Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Get Free Report) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 87,272 shares, a decrease of 39.6% from the August 15th total of 144,506 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 14,783 shares, the days-to-cover ratio is presently 5.9 days.
Nasus Pharma Stock Performance
Nasus Pharma stock traded up $0.07 on Thursday, hitting $3.53. 7,639 shares of the stock traded hands, compared to its average volume of 10,669. Nasus Pharma has a 1 year low of $1.98 and a 1 year high of $9.50. The business’s fifty day simple moving average is $3.47 and its 200 day simple moving average is $3.23.
Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) last released its earnings results on Monday, August 17th. The company reported ($0.27) earnings per share for the quarter. On average, equities analysts forecast that Nasus Pharma will post -0.93 earnings per share for the current fiscal year.
Nasus Pharma Company Profile
Nasus Pharma Ltd. is an Israel-based specialty pharmaceutical company focused on developing intranasal treatments for acute medical conditions. The company’s platform is designed to deliver drug powders through the nose, with the goal of offering convenient, needle-free alternatives to certain injectable therapies.
Nasus Pharma’s development activities center on intranasal pharmaceutical products intended for rapid administration in emergency and urgent-care settings. Its pipeline has included candidates targeting conditions in which fast drug delivery may be important, although the availability and development status of individual products may change as clinical and regulatory work progresses.
The company conducts its research and development activities in Israel and is seeking to advance its intranasal drug-delivery technology for potential use in international markets.
See Also
- Five stocks we like better than Nasus Pharma
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
